Matouš Elphick retweetledi

RESEARCH
5y follow up from the phase 3 KEYNOTE426 trial show that pembrolizumab + axitinib vs sunitinib as 1st line #therapy shows overall & progression free survival benefits in patients with advanced clear cell renal cell carcinoma.
#cancerresearch #clinicaltrials
nature.com/articles/s4159…
English



























